Evidence map›Paper›PMID 28117759›Full record

ArticleCells2017

Vimentin Levels and Serine 71 Phosphorylation in the Control of Cell-Matrix Adhesions, Migration Speed, and Shape of Transformed Human Fibroblasts.

Emmanuel Terriac, Giovanna Coceano, Zahra Mavajian, Tijmen A G Hageman, Andreas F Christ, Ilaria Testa, Franziska Lautenschläger, Annica K B Gad

Open access · goldAbstract read
In one paragraph

Article in Cells, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 53 citations in OpenAlex.

  1. Regulatory T cells attenuate astrogliosis via IL-10/STAT3/PKC/vimentin signaling and promote neurological recovery after spinal cord injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  2. Article
  3. Vimentin - Force regulator in confined environments.Current opinion in cell biology · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Impact of Vimentin on Regulation of Cell Signaling and Matrix Remodeling.Frontiers in cell and developmental biology · 2022
    Review
  15. Review
  16. Article
  17. Article
  18. Targeting cytoskeletal phosphorylation in cancer.Exploration of targeted anti-tumor therapy · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Emmanuel TerriacDepartment of Physics, University of the Saarland, 66123 Saarbrücken, Germany. emmanuel.terriac@physik.uni-saarland.de.
Giovanna CoceanoDepartment of Applied Physics, KTH Royal Institute of Technology, 100 44 Stockholm, Sweden. giovanna.coceano@scilifelab.se.
Zahra MavajianScience for Life Laboratory, Division of Translational Medicine and Chemical Biology, 171 65 Stockholm, Sweden. Mavajian@kth.se.
Tijmen A G HagemanKIST Europe, 66123 Saarbrücken, Germany. t.hageman@kist-europe.de.
Andreas F ChristDepartment of Physics, University of the Saarland, 66123 Saarbrücken, Germany. andreas.f.christ@gmail.com.
Ilaria TestaDepartment of Applied Physics, KTH Royal Institute of Technology, 100 44 Stockholm, Sweden. ilaria.testa@scilifelab.se.
Franziska LautenschlägerDepartment of Physics, University of the Saarland, 66123 Saarbrücken, Germany. f.lautenschlaeger@physik.uni-saarland.de.
Annica K B GadScience for Life Laboratory, Division of Translational Medicine and Chemical Biology, 171 65 Stockholm, Sweden. Annica.Gad@ki.se.
KTH Royal Institute of Technology · SELeibniz-Institute for New Materials · DEScience for Life Laboratory · SEKIST Europe · DESaarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasizing tumor cells show increased expression of the intermediate filament (IF) protein vimentin, which has been used to diagnose invasive tumors for decades. Recent observations indicate that vimentin is not only a passive marker for carcinoma, but may also induce tumor cell invasion. To clarify how vimentin IFs control cell adhesions and migration, we analyzed the nanoscale (30-50 nm) spatial organization of vimentin IFs and cell-matrix adhesions in metastatic fibroblast cells, using three-color stimulated emission depletion (STED) microscopy. We also studied whether wild-type and phospho-deficient or -mimicking mutants of vimentin changed the size and lifetime of focal adhesions (FAs), cell shape, and cell migration, using live-cell total internal reflection imaging and confocal microscopy. We observed that vimentin exists in fragments of different lengths. Short fragments were mostly the size of a unit-length filament and were mainly localized close to small cell-matrix adhesions. Long vimentin filaments were found in the proximity of large FAs. Vimentin expression in these cells caused a reduction in FAs size and an elongated cell shape, but did not affect FA lifetime, or the speed or directionality of cell migration. Expression of a phospho-mimicking mutant (S71D) of vimentin increased the speed of cell migration. Taken together, our results suggest that in highly migratory, transformed mesenchymal cells, vimentin levels control the cell shape and FA size, but not cell migration, which instead is linked to the phosphorylation status of S71 vimentin. These observations are consistent with the possibility that not only levels, but also the assembly status of vimentin control cell migration.

Indexed as

cell migrationfocal adhesionsstimulated emission depletion (STED) microscopytotal internal reflection (TIRF) microscopyvimentin

Identifiers

PMID28117759
PMCPMC5371867
OpenAlexW2580288157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.